Impact of Estrogen + Estradiol Receptor Alpha Modulator Therapy on Oxidative Stress in Post-menopausal Women With and Without Sleep Apnea

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-01

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

One of the most likely mechanisms explaining the sleep apnea (SA)-induced increase in metabolic syndrome is the oxidative stress (OS) induced by intermittent hypoxia (IH). There are clear-cut signs of OS in postmenopausal women that may be further enhanced by SA. In rats exposed to IH, an estradiol receptor alpha agonist decreases the level of OS markers. The aims of this study are to compare OS in apneic and non-apneic postmenopausal women and to demonstrate that OS will improve after 3 months of treatment with ER alpha agonists (Duavive) in apneic post-menopausal women.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Affect of Duavive on Mood & Anxiety Symptoms

NCT04478305

Menopause Depression, Anxiety Sleep +1 more

RECRUITING PHASE1

Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

NCT00592839

Nocturnal Vasomotor Symptoms

COMPLETED PHASE4

Low-dose Hormone Therapy for Relief of Vasomotor Symptoms

NCT00446199

Vasomotor Symptoms Hot Flashes

COMPLETED PHASE3

Raising Insulin Sensitivity in Post Menopause

NCT02274571

Menopause

COMPLETED EARLY_PHASE1

A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)

NCT01015677

Moderate to Severe Vasomotor Symptoms in Postmenopausal Women

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sleep apnoea (SA) is highly prevalent in general population. It is a sex-specific respiratory disease with a lower incidence in women than in men but it increases after menopause. SA and nocturnal intermittent hypoxia (IH) predict the risks of metabolic syndrome independently of obesity, and in patients without comorbidities, SA is associated with insulin resistance. One of the most likely mechanisms explaining the SA-induced increase in metabolic syndrome is the oxidative stress (OS) induced by IH. There are clear-cut signs of OS in postmenopausal women that may be further enhanced by SA resulting in an increased activity of the sympathetic system as well as damages in adipose tissue, blood vessels, and in the liver. Estradiol is a potent antioxidant hormone. Recent experiments conducted in Dr Joseph laboratory demonstrated that in ovariectomized female rats exposed to IH, an ER alpha agonist decreases the level of "Advanced Oxidation Protein Products", prevents excessive mitochondrial ROS production, and the increase of arterial blood pressure. Oestrogens combined with a tissue-specific estradiol receptor modulators (bazedoxifene) are approved and available in Canada (Duavive) for the treatment of vasomotor symptoms and prevention of osteoporosis associated with menopause. The aims of this study are to compare OS in apneic and non-apneic postmenopausal women and to demonstrate that OS will improve after 3 months of treatment with ER alpha agonists (Duavive) in apneic post-menopausal women. 18 newly diagnosed women with untreated severe SA and 18 without SA will be recruited from the sleep clinic. Eligible subjects will be post-menopausal non-smoking women aged 30 to 65 years with a BMI less/equal to 35 kg.m-2, apnoea + hypopnea index \< 15/h (non SA group) or ≥ 30/h (SA group) on a polysomnographic recording. The study will be a prospective comparative trial. Following completion of baseline measurements, subjects will receive 1 tablet of Duavive (0.45 estrogens mg and 20 mg bazedoxifene) daily for 3 months. A follow-up phone call will be completed monthly, and side effects will be recorded. All measurements will be repeated after 3 months of Duavive. The main outcome is the levels of Advanced Oxidation Protein Products and malondialdehyde as a reflect of cellular oxidative damages. The investigators will also measure plasmatic activity of superoxide dismutase and serum nitrite + nitrate levels. Secondary outcomes are related to metabolic (anthropometric variables, biologic markers of glucose homeostasis, lipid profiles, orexin-A and liver function), cardiac health (arterial blood pressure, 24-h heart rate variability to measure cardiac autonomic function) and quality of life. Analysis: Differences between results obtained in each condition will be analysed using ANOVA. Statistical significance will be considered at p\<0.05. Considering the changes in OS observed with hormonal therapy in post-menopausal women and those observed with SA treatment, the sample size was determined to be able to demonstrate a 30 % difference in OS between SA and non-apneic women following 3 month of treatment with Duavive with alpha =0.05, 80% power analysis and a 20% drop-out rate. New avenues in postmenauposal hormonal therapy may have a huge impact on morbidity/mortality and a drug therapy should be more easily accepted that CPAP to reach this goal. These results should open the door to an RCT aimed at quantifying benefits of such treatment on metabolic syndrome features.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep Apnea Post Menopausal Oxidative Stress

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Open label treatment for 3 months in two parallel groups (post menopausal women without and with sleep apnea)

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Post menopausal sleep apnea

Post menopausal women with severe sleep apnea

Group Type EXPERIMENTAL

Duavive (0.45 estrogens mg and 20 mg bazedoxifene)

Intervention Type DRUG

Drug given for 3 months in each participant

Post menopausal non sleep apnea

Post menopausal women without sleep apnea

Group Type EXPERIMENTAL

Duavive (0.45 estrogens mg and 20 mg bazedoxifene)

Intervention Type DRUG

Drug given for 3 months in each participant

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Duavive (0.45 estrogens mg and 20 mg bazedoxifene)

Drug given for 3 months in each participant

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* post-menopausal women
* aged 45 to 65 years
* BMI less/equal 35 kg.m-2,
* apnoea + hypopnea index (AHI) \< 15/h (non SA group) or ≥ 30/h (SA group) on a polysomnographic recording,
* 90% of AHI associated with obstructive events,
* regular exercise, dietary and sleep habits
* free of sleep debt (insomnia, reported habitual sleep time \> 6 h/night),
* stable medical condition.

Exclusion Criteria

* clinically significant diurnal somnolence requiring immediate treatment in SA patients,
* nocturnal hypoventilation (% sleep time below 90% SaO2 \> 10 %, PaCO2 \> 45 mmHg),
* use of hormonal therapy,
* use of any medication with a respiratory depressant effect (narcotics),
* contraindication to the dug used in the protocol

Minimum Eligible Age

45 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No